PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
Evaluating the Evidence for SGLT2 Inhibition in CKD: Highlights From the 2021 Virtual ERA-EDTA Congress
Visit https://www.peervoice.com/BFW860 to view the entire programme with slides. After completing “Evaluating the Evidence for SGLT2 Inhibition in CKD: Highlights From the 2021 Virtual ERA-EDTA Congress”, participants will be able to: Describe key safety and efficacy data on SGLT2 inhibition for the management of chronic kidney disease (CKD); Summarise what the latest data on SGLT2 inhibition add to the current treatment algorithm for CKD; Discuss the clinical implications of SGLT2 inhibition in the context of managing patients with CKD.